Baker Ellis Asset Management LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,712 shares of the biopharmaceutical company’s stock after selling 666 shares during the period. Baker Ellis Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $487,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Retirement Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Orion Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $28,000. Perennial Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $29,000. Founders Capital Management acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $31,000. Finally, Brand Asset Management Group Inc. acquired a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $31,000. 72.41% of the stock is owned by institutional investors.

BMY has been the topic of several research reports. Truist upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. TheStreet upgraded shares of Bristol-Myers Squibb from a “c” rating to a “b” rating in a research note on Thursday, April 29th. Truist Securities upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price objective for the company from $66.00 to $74.00 in a research note on Monday, April 19th. Truist Financial upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Finally, Morgan Stanley lowered shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $70.00 to $62.00 in a research note on Friday. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $73.81.

Shares of Bristol-Myers Squibb stock opened at $63.48 on Tuesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. Bristol-Myers Squibb has a fifty-two week low of $54.07 and a fifty-two week high of $67.16. The firm has a fifty day moving average price of $63.60 and a two-hundred day moving average price of $63.04. The company has a market cap of $141.81 billion, a PE ratio of -577.04, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.08). Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The company had revenue of $11.07 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same period last year, the company earned $1.72 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 2.7% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Thursday, April 1st were paid a $0.49 dividend. This represents a $1.96 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Wednesday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is 41.79%.

In other news, CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $62.20, for a total value of $1,555,000.00. Following the completion of the transaction, the chief executive officer now owns 528,980 shares in the company, valued at approximately $32,902,556. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.14% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Further Reading: What is a Tariff?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.